Q&A With Danny McBryan From Boehringer Ingelheim: Stiolto Provides New Treatment Option For Patients With COPD
With the number of patients diagnosed with COPD continuing to grow new treatment options are also needed to help these patients maintain a sustainable quality of life.
With the number of patients diagnosed with COPD continuing to grow new treatment options are also needed to help these patients maintain a sustainable quality of life.
Danny McBryan, MD, who serves as vice president Clinical Development and Medical Affairs, Respiratory for Boehringer Ingelheim Pharmaceuticals, discussed this new treatment option during the annual CHEST conference in Montreal.
Related Videos
Related Content
